Navigation Links
Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
Date:6/18/2009

Dr. Said Sebti, Chair, Department of Drug Discovery at Moffitt.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center [http://www.moffitt.org/] is an NCI [http://www.cancer.gov/] Comprehensive Cancer Center - a designation that recognises Moffitt's excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network [http://www.nccn.org/index.asp], a prestigious alliance of the country's leading cancer centres, and is listed in U.S. News & World Report ['/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Japanese Cancer Association and Debiopharm Honour Japanese Research
4. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
5. Debiopharm and EPFL Establish an Oncology Chair
6. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
7. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
8. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
9. Digital Healthcare Specialist Cadient Group Ranked #2 on List of Full-service Advertising Agencies in the Philadelphia Region
10. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
11. Cadient Group Brings Home the Gold and Two Bronze Aster Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... RALEIGH, N.C. , Aug. 20, 2014 /PRNewswire/ ... clinical research services located in Raleigh, ... Bradford Evans as Vice President of ... Administration, Brad will oversee all corporate processes, including ... to joining Clintrax Global, Brad worked as an ...
(Date:8/20/2014)... measuring vibrational motion of a single molecule with a ... a single molecule differs from the behaviour of larger ... the University of California, Irvine, where post-doctoral researcher Eero ... visiting fellow under professor Vartkess A. Apkarian, whose team ... by Professor Eric O. Potma. The results of the ...
(Date:8/20/2014)... -- Decision Resources Group finds that the vascular access device market in ... India and China (BRIC) ... the size of the United States market ... faster growth as a result of strong economic expansion, improving access ... from Decision Resources Group,s coverage of the BRIC vascular access device ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... N.J., Sept. 12 Schering-Plough,Corporation (NYSE: SGP ) ... aggregate principal amount of 6.00% Senior Notes due 2017 ... due 2037 through,an underwritten registered public offering. The offering ... customary closing conditions. The global coordinator for the ...
... Inc.,(Nasdaq: MEDX ) announced today that it is ... Growth Conference in New York City on Tuesday,September 18, ... be,webcast live and will be available for replay through ... Medarex website via the Internet at, http://www.medarex.com . ...
... SAN DIEGO, Sept. 12 Gen-Probe Incorporated,(Nasdaq: GPRO ... Bank of,America,s 37th Annual Investment Conference in San Francisco ... (5:30 p.m. Eastern Time).,The presentation is scheduled to be ... the investor information section of Gen-Probe,s website,at http://www.gen-probe.com ...
Cached Biology Technology:Schering-Plough Announces Pricing of Senior Notes Offering 2Schering-Plough Announces Pricing of Senior Notes Offering 3Gen-Probe to Webcast Presentation at Bank of America's 37th Annual Investment Conference 2
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... the journal Carcinogenesis by researchers at the ... protein adenomatous polyposis coli (APC) in suppressing colorectal cancer ... U.S. , Lead author Kristi Neufeld, associate professor in ... Cancer Biology program at the KU Cancer Center, has ... understand the various activities of APC, a protein whose ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3New feeding tube connectors will improve patient safety 2
... at Universitat Autnoma de Barcelona (INc-UAB) identified the fundamental ... associated with synaptic activity. The discovery, published in the ... study a new target that could help to understand ... known to cause early cognitive deficit, and the neurodegeneration ...
... NC In a paper published today in the journal ... North Carolina at Chapel Hill demonstrates a simple, cost-effective technique ... the structures, and ultimately the functions, of the RNA molecules ... When cell behavior goes wrong, diseases including cancer and ...
... gene sequencing technology, researchers have demonstrated that the gene ... Leukemia, AML, one of the most common types of ... allows for the rapid and comprehensive detection of gene ... online April 15 in Nature , are a ...
Cached Biology News:Researchers have identified a gene with a key role in neuronal survival 23-D RNA modeling opens scientific doors 2Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia 2
... U. Desselberger (1995) • This book ... together classical and molecular techniques currently ... infections and analysis of virus-specific antibodies ... are presented covering immunoassays, blotting and ...
...
... Kits provide rapid and efficient removal of ... and salts from PCR products (Figure 1). ... two Binding Buffer options for fragments >100 ... performed in either single column or 96-well ...
... Blunt TOPO PCR Cloning Kit offers ... high-efficiency (>=95%) cloning of blunt-end PCR ... The kit includes the linearized and ... 5-minute bench-top ligations without ligase (1). ...
Biology Products: